Bowel Cancer
The National Bowel Cancer Screening Program (NBCSP) offers free home test kits every two years to all eligible people aged 45–74. From 1 July 2024, the program has lowered the eligible screening age from 50 to 45 years. People aged 45–49 can request their first bowel cancer screening kit while people aged 50-74 will continue to receive a kit every 2 years from the NBCSP.

Bowel screening participation data is coming soon.
In the meantime, you can obtain participation data from the Australian Institute for Health and Welfare (AIHW) using the link below or please select “Screening numbers” in the menu above to view key insights and data on the number of people screened for bowel cancer in Victoria. Please note: Figures may vary between reports due to differences in the calculation method.
AIHW bowel screening participation data391,740 eligible people aged 50-74
Definition
Number of persons aged 50-74 completing a bowel screening test under the National Bowel Cancer Screening Program (NBCSP) in Victoria.
From 1 July 2024, the program has lowered the eligible screening age from 50 to 45 years. The 2023 Annual Statistical Report includes data only up to the end of 2023, so data for the 45-49 age group is not included.
Interpretation
This indicator is a crude measure of persons who completed a bowel screening test in 2023. In contrast, a calculated participation rate takes the total number of eligible persons invited in 2023 as the denominator and accounts for a range of other factors which may have precluded participation (e.g. out-migration).
The number of persons screened in 2023 remained higher in females compared to males across all age groups. The increased screening activity across Victoria in 2023 may be due to a number of factors, including the National and State bowel screening campaigns and other screening activities delivered in 2023, including improved access to kits via the Alternative Access Model and NCSR, as well as the higher number of invitations issued in the March quarter 2023 as indicated by the Australian Institute of Health and Welfare.
Additionally, total screening volumes were closely aligned with LPHU population sizes, with larger populations (e.g. NEPHU and SEPHU) corresponding to higher screening volumes and smaller populations (e.g. Ovens-Murray and Goulburn Valley) associated with lower screening volumes. This trend was consistent for screening volumes and PHN population sizes.
Targeted interventions for specific age groups may assist in maintaining this encouraging increase in screening.
Note: The National Bowel Cancer Screening Program was introduced in phases and did not reach full implementation until 2020. As a result, the number of screenings and the pool of eligible participants varied over time, and the comparisons with data prior to and after 2020 are not recommended.
75.9% of participants
Time to Colonoscopy
Definition:
Time to colonoscopy is the number of days between the date of the positive bowel screening test result and the date of the first subsequent colonoscopy. Reported as a percentage, calculated as follows.
- Numerator: Number of participants who returned a positive bowel screening test result and proceeded to colonoscopy as requested.
- Denominator: Total number of participants returning a positive bowel screening test result and being requested for a follow-up colonoscopy.
Colonoscopies performed within 4 months after a positive bowel screening test are considered timely as per clinical guidelines.
Interpretation
The proportion of participants attending for colonoscopy within 4 months of a positive screening test slightly increased overall, with 75.9% of participants attending within four months in 2023 compared with 73.2% in 2022.
84% of participants overall attended for their recommended colonoscopy within 6 months in 2023.
The percentage of females attending for a colonoscopy in a timely manner (within 4 months of a positive screening test) has been consistently higher than males since 2018 which could partly be due to a higher likelihood among females to engage in health seeking behaviours. However, this gap appears to be narrowing over time from a 7% difference between females and males in 2018 to a 4% difference in 2023.
Looking at the geographic stratification at Local Public Health Unit (LPHU) level, the proportion of participants attending a colonoscopy within 4 months of a positive screening test for the metropolitan LPHUs ranged from 72% to 79%, whilst the proportion for regional LPHUs ranged from 67% to 80%.
Ongoing efforts are required at both the health systems and individual level to ensure that eligible participants have timely access to, and understand the importance of, colonoscopy for detection of bowel cancer at an earlier stage for improving health outcomes. 90% of bowel cancers can be treated successfully if detected early.